NIVF
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E and P/B are superficially attractive but misleading due to the -349% operating margin.
- Extremely low P/E (0.06)
- Low P/B (0.02)
- Valuation metrics are distorted by one-time gains
- Market cap is negligible
Revenue growth is irrelevant when operating margins are deeply negative.
- 11.9% Revenue growth
- Core business is hemorrhaging cash
- No evidence of a turnaround strategy
Historical price performance is indicative of a total loss of investor confidence.
- 99.8% loss in value over 12 months
- Consistent downward trend
Balance sheet looks stable on paper, but the income statement is broken.
- Piotroski F-Score 5/9
- Low leverage
- Negative ROA (-36.94%)
- Missing Altman Z-Score
Company is in no position to return capital.
- No dividend payments
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NIVF and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NIVF
NewGenIvf Group Limited
Primary
|
-100.0% | -100.0% | -99.8% | -98.0% | -6.4% | +9.4% |
|
LYRA
Lyra Therapeutics, Inc.
Peer
|
-99.9% | -99.5% | -87.8% | -91.8% | -50.8% | +32.6% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ONCO
Onconetix, Inc.
Peer
|
-100.0% | -100.0% | -97.2% | -95.7% | -70.5% | -32.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NIVF
NewGenIvf Group Limited
|
BEARISH | $1.25M | 0.06 | 79.4% | 209.0% | $2.19 | |
|
LYRA
Lyra Therapeutics, Inc.
|
BEARISH | $1.15M | - | -6595.0% | -% | $0.65 | Compare |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
ONCO
Onconetix, Inc.
|
BEARISH | $0.55M | - | -115.5% | -% | $0.76 | Compare |
Past News Coverage
Recent headlines mentioning NIVF from our newsroom.